- Home
- BCS vs TAK Comparison
BCS vs TAK Comparison
Compare BCS & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCS | TAK |
|---|---|---|
| Founded | 1690 | 1781 |
| Country | United Kingdom | Japan |
| Employees | 98141 | 47455 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.5B | 56.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BCS | TAK |
|---|---|---|
| Price | $21.14 | $18.39 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.9M | 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 2.15% | ★ 2.86% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.98 | $0.04 |
| Revenue Next Year | $4.36 | $0.92 |
| P/E Ratio | ★ $10.92 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.14 | $12.99 |
| 52 Week High | $27.70 | $18.82 |
Technical Indicators
Market Signals| Indicator | BCS | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 32.38 | 58.01 |
| Support Level | $20.71 | $17.51 |
| Resistance Level | $22.64 | $18.82 |
| Average True Range (ATR) | 0.64 | 0.24 |
| MACD | -0.25 | -0.08 |
| Stochastic Oscillator | 13.72 | 68.88 |
Price Performance
Historical ComparisonAbout BCS Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via five principal segments; Barclays UK (retail), UK corporate bank, private bank and wealth management, investment bank, and US consumer bank. In its UK segment, the bank provides current accounts, mortgages, savings and investment management services, credit cards, and business banking services to retail clients and small and medium-size enterprises. The US consumer bank includes a co-branded credit card and unsecured lending business. The investment bank offers global markets, financing, and advisory services.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.